Geulah Livshits analyst CHARDAN CAPITAL

Currently out of the existing stock ratings of Geulah Livshits, 265 are a BUY (97.79%), 6 are a HOLD (2.21%).

Geulah Livshits

Work Performance Price Targets & Ratings Chart

Analyst Geulah Livshits, currently employed at CHARDAN CAPITAL, carries an average stock price target met ratio of 31.97% that have a potential upside of 53% achieved within 165 days.

Geulah Livshits’s has documented 475 price targets and ratings displayed on 37 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on MGX, Metagenomi, Common Stock at 07-Jul-2026.

Wall Street Analyst Geulah Livshits

Analyst best performing recommendations are on PDSB (PDS BIOTECHNOLOGY CORP).
The best stock recommendation documented was for PDSB (PDS BIOTECHNOLOGY CORP) at 5/20/2021. The price target of $11 was fulfilled within 7 days with a profit of $3.73 (51.31%) receiving and performance score of 73.3.

Average potential price target upside

CRSP Crispr Therapeutics AG EDIT Editas Medicine IOVA Iovance Biotherapeutics MRNA Moderna NTLA Intellia Therapeutics RCKT Rocket Pharmaceuticals RGNX Regenxbio KRYS Krystal Biotech SLDB Solid Biosciences LLC TSHA Taysha Gene Therapies  VYGR Voyager Therapeutics FIXX Homology Medicines IMTX Immatics NV LOGC LogicBio Therapeutics TNYA Tenaya Therapeutics VINC Vincerx Pharma PRVB Provention Bio CABA Cabaletta Bio MGTX MeiraGTx Holdings PLC PASG Passage Bio SQZ Sqz Biotechnologies Co ACHL Achilles Therapeutics PLC ADR IMNM Immunome  IMRX Immuneering Corp IPSC Century Therapeutics FDMT 4D Molecular Therapeutics  CRGX CARGO Therapeutics, Common Stock LXEO Lexeo Therapeutics, Common Stock MGX Metagenomi, Common Stock SNTI Senti Biosciences ACH Aluminum Corp of China Ltd ADR PR Permian Resources PRME Prime Medicine, Common Stock RC Ready Capital Corp RCOR Renovacor VBLT Vascular Biogenics Ltd PDSB PDS Biotechnology Corp

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Hold Since 11-Jun-2026

$60

$5.08 (9.25%)

$32

1 months 15 days ago
(11-Jun-2026)

8/9 (88.89%)

$9.77 (19.45%)

254

Buy Since 18-Apr-2024

$82

$27.08 (49.31%)

$77

2 months 20 days ago
(06-May-2026)

10/19 (52.63%)

$26.92 (48.87%)

160

Buy Since 17-Jan-2018

$110

$55.08 (100.29%)

$105

4 months 9 days ago
(17-Mar-2026)

27/36 (75%)

$59.91 (119.60%)

235

Buy Since 28-Oct-2019

$76

$21.08 (38.38%)

$74

5 months 9 days ago
(17-Feb-2026)

2/16 (12.5%)

$22.83 (42.94%)

24

Buy Since 16-Feb-2022

$82

$27.08 (49.31%)

$80

5 months 13 days ago
(13-Feb-2026)

8/27 (29.63%)

$28.93 (54.51%)

214

Show more analysts

Please expand the browser size to see the chart

Which stock is Geulah Livshits is most bullish on?

Potential upside of $29.46 has been obtained for CRSP (CRISPR THERAPEUTICS AG)

Which stock is Geulah Livshits is most reserved on?

Potential downside of -$12.19 has been obtained for KRYS (KRYSTAL BIOTECH)

What Year was the first public recommendation made by Geulah Livshits?

On 2019

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?